Deutsche Bank has issued an optimistic forecast for Eli Lilly (LLY) and raised the pharmaceutical stock’s rating from “Hold” to “Buy.” The price target was raised by $300 to a total of $1,025 per share. James Shin, an analyst at Deutsche Bank, explains the pharmaceutical company’s forecast and outlook at Catalysts. Shin says the biggest […]